United Therapeutics [UTHR] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

United Therapeutics

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: United Therapeutics wins in 15 metrics, Haleon Plc - ADR wins in 4 metrics, with 0 ties. United Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricUnited TherapeuticsHaleon Plc - ADRBetter
P/E Ratio (TTM)16.9219.93United Therapeutics
Price-to-Book Ratio2.685.08United Therapeutics
Debt-to-Equity Ratio0.0053.41United Therapeutics
PEG Ratio1.7721.36United Therapeutics
EV/EBITDA10.1133.86United Therapeutics
Profit Margin (TTM)40.36%13.81%United Therapeutics
Operating Margin (TTM)45.64%22.21%United Therapeutics
EBITDA Margin (TTM)45.64%22.21%United Therapeutics
Return on Equity19.30%9.38%United Therapeutics
Return on Assets (TTM)12.96%4.61%United Therapeutics
Free Cash Flow (TTM)$1.08B$2.67BHaleon Plc - ADR
Dividend YieldN/A1.63%N/A
1-Year Return24.59%-14.37%United Therapeutics
Price-to-Sales Ratio (TTM)6.373.63Haleon Plc - ADR
Enterprise Value$16.14B$119.46BHaleon Plc - ADR
EV/Revenue Ratio5.248.07United Therapeutics
Gross Profit Margin (TTM)89.03%55.38%United Therapeutics
Revenue per Share (TTM)$69$2United Therapeutics
Earnings per Share (Diluted)$25.12$0.45United Therapeutics
Beta (Stock Volatility)0.620.24Haleon Plc - ADR
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

United Therapeutics vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

United Therapeutics
Haleon Plc - ADR
United Therapeutics Stock Overview | Haleon Plc - ADR Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
United Therapeutics1.20%4.24%9.54%50.21%42.01%23.10%
Haleon Plc - ADR-1.44%1.83%-9.02%-13.45%-12.60%-5.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
United Therapeutics24.59%114.46%326.34%258.80%694.13%1,312.23%
Haleon Plc - ADR-14.37%45.81%19.84%19.84%19.84%19.84%

News Based Sentiment: United Therapeutics vs Haleon Plc - ADR

United Therapeutics

News based Sentiment: MIXED

September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.

View United Therapeutics News Sentiment Analysis

Haleon Plc - ADR

News sentiment data is not available for Haleon Plc - ADR at this time.

Performance & Financial Health Analysis: United Therapeutics vs Haleon Plc - ADR

MetricUTHRHLN
Market Information
Market Cap i$19.33B$41.72B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i924,0019,529,570
90 Day Avg. Volume i904,0248,844,817
Last Close$443.44$8.88
52 Week Range$266.98 - $444.57$8.71 - $11.42
% from 52W High-0.25%-22.24%
All-Time High$444.57 (Oct 02, 2025)$11.42 (Jun 02, 2025)
% from All-Time High-0.25%-22.24%
Growth Metrics
Quarterly Revenue Growth0.12%-0.01%
Quarterly Earnings Growth0.11%0.33%
Financial Health
Profit Margin (TTM) i0.40%0.14%
Operating Margin (TTM) i0.46%0.22%
Return on Equity (TTM) i0.19%0.09%
Debt to Equity (MRQ) i0.0053.41
Cash & Liquidity
Book Value per Share (MRQ)$158.65$1.77
Cash per Share (MRQ)$67.41$0.08
Operating Cash Flow (TTM) i$1.37B$3.34B
Levered Free Cash Flow (TTM) i$811.05M$2.58B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: United Therapeutics vs Haleon Plc - ADR

MetricUTHRHLN
Price Ratios
P/E Ratio (TTM) i16.9219.93
Forward P/E i15.2521.36
PEG Ratio i1.7721.36
Price to Sales (TTM) i6.373.63
Price to Book (MRQ) i2.685.08
Market Capitalization
Market Capitalization i$19.33B$41.72B
Enterprise Value i$16.14B$119.46B
Enterprise Value Metrics
Enterprise to Revenue i5.248.07
Enterprise to EBITDA i10.1133.86
Risk & Other Metrics
Beta i0.620.24
Book Value per Share (MRQ) i$158.65$1.77

Financial Statements Comparison: United Therapeutics vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)UTHRHLN
Revenue/Sales i$794.40M$3.72B
Cost of Goods Sold i$92.50M$1.66B
Gross Profit i$701.90M$2.06B
Research & Development i$149.00M$105.17M
Operating Income (EBIT) i$382.80M$471.91M
EBITDA i$449.40M$488.09M
Pre-Tax Income i$423.50M$388.31M
Income Tax i$101.30M$88.99M
Net Income (Profit) i$322.20M$299.32M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)UTHRHLN
Cash & Equivalents i$1.90B$911.46M
Total Current Assets i$3.94B$5.59B
Total Current Liabilities i$721.50M$6.42B
Long-Term Debt iN/A$10.30B
Total Shareholders Equity i$6.81B$21.57B
Retained Earnings i$7.54B$36.76B
Property, Plant & Equipment i$0$2.52B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)UTHRHLN
Operating Cash Flow i$463.80MN/A
Capital Expenditures i$-74.90MN/A
Free Cash Flow i$386.30MN/A
Debt Repayment i$-100.00MN/A
Common Stock Repurchase i$0N/A

Short Interest & Institutional Ownership Analysis

MetricUTHRHLN
Shares Short i2.78M15.71M
Short Ratio i3.121.93
Short % of Float i0.08%0.00%
Average Daily Volume (10 Day) i924,0019,529,570
Average Daily Volume (90 Day) i904,0248,844,817
Shares Outstanding i44.83M12.25B
Float Shares i42.01M8.99B
% Held by Insiders i0.02%0.00%
% Held by Institutions i1.00%0.13%

Dividend Analysis & Yield Comparison: United Therapeutics vs Haleon Plc - ADR

MetricUTHRHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025